RHEOS MEDICINES
Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. Their approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease they are bringing precision to the treatment of immune-mediated diseases. They have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team.
RHEOS MEDICINES
Industry:
Biopharma Biotechnology Health Care
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.rheosrx.com
Total Employee:
11+
Status:
Active
Contact:
857-777-4242
Email Addresses:
[email protected]
Total Funding:
60 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Sitelinks Search Box
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Third Rock Ventures
Third Rock Ventures investment in Series A - Rheos Medicines
Key Employee Changes
Official Site Inspections
http://www.rheosrx.com
- Host name: 104.21.112.1
- IP address: 104.21.112.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Rheos Medicines"
Rheos Medicines - Crunchbase Company Profile
Contact Email [email protected] Phone Number 857-777-4242 Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease.See details»
Rheos Medicines - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Rheos Medicines. Use the PitchBook Platform to explore the full profile.See details»
Rheos Medicines Company Profile - Office Locations, Competitors …
Rheos Medicines (formerly known as Immunometabolism Newco) is a biopharmaceutical company that develops medicines for metabolic pathways in immune cells. It offers …See details»
Rheos Medicines Announces Worldwide Collaboration with Roche …
Dec 19, 2019 · CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class …See details»
Rheos Medicines - Overview, News & Similar companies - ZoomInfo
May 9, 2022 · Rheos Medicines contact info: Phone number: (857) 777-4242 Website: www.rheosrx.com What does Rheos Medicines do? Rheos Medicines is a biopharmaceutical …See details»
Rheos Medicines - VentureRadar
Website: http://www.rheosrx.com/ Develops precision medicine therapies for autoimmune diseases using immunometabolism insights, leveraging a proprietary platform to analyze multi …See details»
Rheos Medicines Announces Worldwide Collaboration with Roche …
Dec 19, 2019 · Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune …See details»
Rheos Medicines Forms Research Collaboration With ... - Business …
Oct 27, 2021 · CAMBRIDGE, Mass. & MARSEILLE, France-- ( BUSINESS WIRE )-- Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment …See details»
Rheos Medicines Announces New Scientific Advisory Board …
Apr 14, 2022 · Rheos Medicines is a biopharmaceutical company developing precision medicines to treat autoimmune and inflammatory diseases by identifying and targeting the molecular …See details»
Rheos Medicines and PatientsLikeMe Announce Strategic …
Dec 17, 2020 · Rheos will incorporate de-identified patient-reported data from PatientsLikeMe along with proteomic, metabolomic, transcriptomic, and genetic data collected from …See details»
Rheos Medicines to Present Data at ACR 2021 for MALT1
Oct 13, 2021 · Rheos Medicines today announced it will present two poster presentations at ACR Convergence 2021, the annual meeting of the American College of Rheumatology which will …See details»
Rheos Medicines Presents Data Demonstrating Potential of MALT1 ...
Nov 1, 2021 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Rheos Medicines, Inc., a biopharmaceutical company bringing molecular targeting and precision treatment to …See details»
Rheos Medicines to Present at the Cowen and Company 40
Feb 18, 2020 · Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe autoimmune …See details»
Rheos Medicines Receives FDA “Study May Proceed ... - Business …
Jul 20, 2022 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Rheos Medicines, a biopharmaceutical company bringing molecular targeting and precision treatment to autoimmune and …See details»
Rheos Medicines - VentureRadar
Similar Companies: Sitryx United Kingdom Privately Held We’re altering immune cell metabolism to resolve disease. Metabolic changes within cells of the immune system can drive the …See details»
Rheos Medicines Announces Publication of New Data to Support …
May 9, 2022 · Rheos Medicines today announced the peer-reviewed publication of preclinical data supporting MALT1 inhibition as a novel therapeutic strategy to treat autoimmune and …See details»
免费的新药情报数据库 - 药品查询、药品数据库、医药数据
Abstract A number of receptors are capable of activating the PI3K pathway in T cells, most prominently the T-cell receptor for antigen (TCR), the costimulatory receptor CD28, and the …See details»
Rheos Medicines to Present Data at ACR 2021 for MALT1 …
Oct 13, 2021 · Rheos Medicines is a biopharmaceutical company developing novel, small molecule medicines to treat autoimmune and inflammatory diseases with greater precision by …See details»
Rheos Medicines to Present Data at ASH 2021 for MALT1
Nov 4, 2021 · Rheos Medicines is a biopharmaceutical company developing novel, small molecule medicines to treat autoimmune and inflammatory diseases with greater precision by …See details»
Rheos Medicines Presents New Data Supporting MALT1
Dec 13, 2021 · Rheos’s lead product candidate, RHX-317, is a novel, small molecule MALT1 inhibitor initially in development for the treatment of chronic GVHD. The data will be presented …See details»